6 reports of this reaction
1.3% of all AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE reports
#18 most reported adverse reaction
APPLICATION SITE RASH is the #18 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, manufactured by Kenvue Brands LLC. There are 6 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE to APPLICATION SITE RASH. This represents approximately 1.3% of all 448 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE who experience application site rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE RASH is a less commonly reported adverse event for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, but still significant enough to appear in the safety profile.
In addition to application site rash, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to application site rash in FDA adverse event reports:
APPLICATION SITE RASH has been reported as an adverse event in 6 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE RASH accounts for approximately 1.3% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, making it a notable side effect.
If you experience application site rash while taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.